The global market for cannabidiol (CBD), valued at US$9.3 billion
By 2020, it is expected to reach US$23.6 billion in revenue by 2025. From 2019 to 2025, the compound annual growth rate is expected to reach 22.2%. For companies that use the explosive popularity of CBD, the future prospects are very broad.
North America continues to occupy 40% of the global market share
, But it may not dominate for a long time. Europe is closing the gap and its market share is expected to be 31%
Go beyond the geographic needs of North America.
As a global leader in the end-to-end development and manufacturing of innovative cannabinoid products,
Can well meet the international demand for CBD. By providing customized services ranging from plant processing and extraction to product development, analytical testing and white labeling, Valens is the preferred partner of companies in the CBD health industry.
In Europe, the legality of cannabis varies from country to country, and many countries only allow medical use. Although technically still operating in a legal gray area due to certain definitions that determine whether plants are considered cannabis, the use of cannabis-derived CBD products for recreational purposes has been allowed to a large extent. Product quality, inconsistencies and regulatory issues limit market growth and threaten consumer safety.
Estimated value of 1.5 billion euros
By 2023, the European CBD market has matured and has huge potential
. November 2020
A landmark ruling made by the European Court of Justice ruled that CBD is not a narcotics and therefore can be sold freely in the EU. This ruling has laid a clearer regulatory path for the legal use of CBD, which is beneficial to companies that produce high-quality CBD products.
In addition to the demand for traditional CBD hemp products, Valens is actively engaged in the development of health-centric product solutions. It is estimated that CBD products may account for more than 0.15%
By 2028, the overall health and healthcare market share of this market will reach this level. Valens is committed to working with brands to attract new consumer groups who have never used cannabis before: With the advancement of technology and product innovation, the potential for CBD to be integrated into health categories is essentially unlimited.
As legislation lags behind consumer demand, imitations and false product claims weaken the market potential to focus on business excellence. In this fast-developing market, there are many consumers who want to use CBD, but because they are not familiar with the market, they are not clear on how to choose the best product for them. For companies investing in high-quality, compliant CBD products, consumer training and quality assurance are essential.
Cannabis (C.bis sativa, L.) contains more than 120 phytocannabinoids
, A plant compound with the potential to activate receptors in the endocannabinoid system
. THC and CBD are the most commonly used and studied cannabinoids, although ongoing research involves the therapeutic potential of many lesser-known cannabinoids such as cannabinoids (CBC) and cannabinoids (CBN). From a health perspective, CBD continues to stand out for its therapeutic potential.
A large number of preliminary studies have shown that CBD can provide a variety of potential health benefits. The European Court of Justice’s recent ruling on the status of CBD as a non-narcotics has opened the way for increasingly powerful research opportunities.
Currently only one pharmaceutical product containing CBD is approved for use in the EU: Epidyolex®
, Used as an adjunctive treatment for seizures associated with Lennox-Gastaut and Dravet syndrome. At the same time, CBD has become more and more popular in the healthcare industry due to its potential to relieve pain.
And reduce inflammation
Both CBD oil and hemp seed oil are non-toxic oils extracted from the hemp plant. However, they are completely different products in terms of creation and market presentation.
Hemp seed oil
It is only extracted from hemp seeds and produced by cold pressing. Hemp seeds contain almost no cannabinoids and are therefore not a known source of CBD. Hemp seed oil is rich in omega-3 and omega-6 fatty acids, which can provide various nutritional benefits through consumption. It can also be used topically to relieve dry skin
CBD oil or hemp extract is extracted from the hemp plant by using solvents such as CO2 or ethanol. CBD can be extracted from the inflorescence of plants, or from the whole plant.
Some manufacturers try to claim that hemp seed oil products have the same potential benefits as CBD. By increasing customer education and awareness, as well as regulatory guidelines for the labeling and testing of healthcare products, the differences between the two products will be transparent to consumers.
Another confusing area in CBD is plant sources. Both the drug type cannabis and cannabis are derived from the same plant variety of cannabis (Cannabis sativa L). In Europe, any cannabis plant that contains more than 0.2% THC (by dry weight) is considered a drug type of cannabis. Anything below this threshold is considered marijuana.
The cannabis secreted by the cannabis plant can maintain a consistent cannabinoid ratio, which means that medicinal cannabis with a higher THC concentration usually produces more CBD by volume than cannabis. Regardless of the plant source, CBD is consistent at the molecular level.
Without the need for validated testing, the advertised CBD content of many cannabinoid products often does not match the actual measured CBD content. For example, recent analysis
Among the 29 over-the-counter CBD products in the United Kingdom, it was found that most of the tested products (62%) contained no more than 10% of the amount required on the label. The result is between 0% and 155% on the product label. This data supports other comparative studies
The label is not accurate.
CBD is considered to have low abuse potential
No serious adverse effects
At higher doses, product mislabeling is not necessarily related to safety. However, mislabeling of products may lead to inefficiency and negative experiences, which may lead to a weaker consumer perception of the potential benefits of CBD. Therefore, proven performance testing and accurate labeling are critical to building consumer trust.
The extraction methods and processing levels required to produce CBD for ingredient purposes depend on the desired final product. To meet changing needs, Valence provides a complete set of proprietary extraction services, including the extraction of carbon dioxide, ethanol, hydrocarbons, solvent-free and terpenes.
Usually, the initial extraction will produce oleoresin rich in cannabinoids and terpenes. The extract must be antifreeze treatment to remove contaminants (wax and lipids), and then it can be considered an ingredient. If it is necessary to remove terpenes and cannabinoids other than CBD, it can be further purified. For example, the overwintered resin can be distilled to produce a purified CBD distillate without terpenes, or it can even be further refined by crystallization or chromatography to produce a CBD isolate with 99% purity and no other cannabinoids. Depending on the type of final product and the desired characteristics, extracts of different purity are used.
In the past, the CBD market has always been dominated by the demand for edible oil. Due to processing reasons, there are some important differences between different types of oils and their ingredients:
Miscibility is one of the obstacles to the integration of CBD oil into health products: the integration of oil-based ingredients into products that are usually water-based brings product separation challenges. If not managed properly, it may lead to inconsistent dosages and incorrect labeling.
Valence did not overcome the obstacles of oil-water mixing, but found a solution to the problem and obtained an expanded license for development and distribution.
. In the international market, Valens enables European partners to convert any CBD oil into a water-soluble emulsion.
The emulsion is a stable mixture of oil-soluble (CBD) and water-soluble ingredients. Valens' SōRSE is an emulsion technology that has been proven to be stable for up to 12 months. Through a repeatable design, SōRSE eliminates product variability and produces a homogeneous CBD emulsion. Products made by Valens with SōRSE are not subject to the common concerns of product separation, such as creams, clarification and/or precipitation.
Valens' SōRSE is available in liquid, standard powder and agglomerated powder forms to seamlessly integrate CBD into almost all products. Fully customizable, it also allows the development of unique product specific formulations. In the case of low sensory impact, the flavor and aroma desired by consumers become possible.
From CBD fudge, chocolate cake and chocolate, to beverage and gel capsule supplements, CBD consumables market
Is expanding dramatically. Products made by Valens with SōRSE are not subject to the common concerns of product separation, such as creams, clarification and/or precipitation. By using the SōRSE of Valens technology, CBD can be accurately injected into any food or beverage product with food-grade quality control, safety and predictability. Valens uses SōRSE to start eating and offsetting foods more quickly, thereby bringing consumers a more predictable and controllable experience.
Many users prefer digestibility and ease of use, and therefore prefer edible foods. In the health sector, consumers also prefer products that can be used to supplement their lifestyles. In response to this demand, Valens provides customizable product formats in the form of carbonated drinks, drip drinks, cans, bottles and small bottles, and these products do not have the aroma or taste of cannabis.
Topical health products containing CBD come in many forms, including lotions, creams, balms and sprays. These products may act on endocannabinoid receptors
Suitable for muscle tissue, skin and nerve area.
In recent years, cannabinoid receptors in the skin have become the subject of many studies. Preclinical studies
It shows that cannabinoids are actively involved in maintaining skin homeostasis, including inflammation, barrier formation and regulation; therefore, people are interested in the potential of CBD as a topical product to promote skin health.
High-quality topics are not limited to a single ingredient, but can provide multiple levels. Valens uses ethical and sustainable ingredients that consumers can trust, such as soothing aloe vera and nourishing shea butter, to enhance basic product formulations and customer experience.
With great potential for innovation and new product development, the industries that CBD health products can enter are vast. Popular product areas include bath bombs, body scrubs, massage oils and privacy products. Many of these products have the potential to promote relaxation or relieve muscle soreness, but their effectiveness is only the same as the delivery method. Valens' formula is the product of extensive research and development, working in conjunction with already trusted ingredients such as menthol and arnica.
Vaporizers remain popular because of their fast action, caution and portability. Through inhalation, CBD enters the lungs and enters the blood, and circulates in the blood to the brain and other parts of the body. Different from foods that undergo first-pass metabolism
In the liver, inhaled CBD takes a more direct route.
As an industry leader in evaporator production, Valens provides a comprehensive solution for customizable white label vape products. Valens has a wide range of hardware options, including general-purpose ink cartridges and disposable devices, and maintains strict quality standards to ensure consumer safety.
Not all CBD products are created equal. For example, in a recent study
Among 67 CBD foods, 25% of the samples found THC contamination was higher than the lowest level observed. If consumers buy products that contain THC and have no THC, then they are at risk of experiencing a negative experience, which may prevent them from returning to the product.
The unclear definition of cannabis and the lack of verified testing requirements have left room for undertested products to be sold on the market. Insufficient testing will also leave room for the residue of other contaminants (such as heavy metals, microorganisms, pesticides, mycotoxins and residual solvents).
Valens Labs is an analytical testing facility dedicated to quality control. In cooperation with Thermo Fisher Scientific, Valens Labs established the Plant Science Center of Excellence. The laboratory is
Valens Labs has been recognized and operated by the gold standard in laboratory testing services, and even exceeds the most stringent requirements to achieve industry-leading analysis.
In the past, Europe lacked clear regulations and imposed many restrictions on CBD products, restricting the development of the safety market. As a result, unverified statements and product declarations, as well as products that do not meet safety standards or quality controls, are put on the market, thereby misleading consumers.
As legislation tends towards regulations and guidelines, including requirements for label accuracy and quality assurance, the demand for healthy CBD products will continue to expand. This creates huge opportunities for established brands in the health and wellness, food and beverage, and cosmetic industries.
Valence is committed to becoming the preferred partner of international brands pursuing excellence. By providing
In the store's business model, health companies can leverage Valens' extensive experience in cannabis-based science and technology.
Through first-class extraction and analysis tests, Valens only produces the highest quality extracts. Partners can rest assured that their products will meet regulatory requirements and contain no contaminants or fillers. In terms of formulation, product development, white labeling and custom manufacturing, Valens provides a full range of services that can meet the growing needs of the healthcare industry.